Abstract

Research Article

Evaluation of influence of IL-6 C-572G gene polymorphism and clinical factors on positive platelet antibody test

Jeong-Shi Lin*, Li-Hsuan Lee, Hsueng-Mei Liu, Ying-Ju Chen and Tzeon-Jye Chiou

Published: 15 January, 2021 | Volume 4 - Issue 1 | Pages: 006-012

Background: Interleukin-6 (IL-6) promotes antibody production. The objective of this study was to investigate whether IL-6 C-572G single nucleotide polymorphisms (SNP) and clinical factors are associated with positive platelet antibody test.

Materials and methods: Thirty platelet recipients with platelet antibodies (responders) and 20 platelet recipients without platelet antibodies (non-responders) were randomly selected. The -572 C>G (rs 1800796) SNPs in the promoter region of IL-6 gene were genotyped by polymerase chain reaction (PCR)-restriction fragment length polymorphism (RFLP) method. Solid phase red cell adherence assay (SPRCA) was used for platelet antibody detection.

Results: Age, sex, percentage patients with benign diseases, and percentage of patients with homozygotes for the C allele at position -572 of the IL-6 gene were similar between responders and non-responders. Although the amounts of platelets pheresis transfused to patients with hematologic diseases were higher than those of non-hematologic diseases (47.2 ± 54.2 vs. 17.4 ± 13.8 units, p = 0.019), detection rate of platelet antibodies was lower in patients with hematologic diseases than that in patients with non-hematologic diseases (42.3% vs. 79.2%, p = 0.01).

Conclusion: There was no association between IL-6 C-572G gene polymorphism and positive reactivity in solid phase platelet antibody detection method in platelet recipients.

Read Full Article HTML DOI: 10.29328/journal.japch.1001023 Cite this Article Read Full Article PDF

Keywords:

Interleukin-6; Single nucleotide polymorphism; Platelet antibody; Transfusion

References

  1. Cid J, Ortin X, Elies E, Castella D, Panades M, et al. Absence of anti-D alloimmunization in hematologic patients after D-incompatible platelet transfusions. Transfusion. 2002; 42: 173-176. PubMed: https://pubmed.ncbi.nlm.nih.gov/11896331/
  2. Hirano T, Akira S, Taga T, Kishimoto T. Biological and clinical aspects of interleukin 6. Immunol Today. 1990; 11: 443-449. PubMed: https://pubmed.ncbi.nlm.nih.gov/2127356/
  3. Akira S, Taga T, Kishimoto T. Interleukin-6 in biology and medicine. Adv Immunol. 1993; 54: 1-78. PubMed: https://pubmed.ncbi.nlm.nih.gov/8379461/
  4. Rieckmann P, D'Alessandro F, Nordan RP, Fauci AS, Kehrl JH. IL-6 and tumor necrosis factor-alpha. Autocrine and paracrine cytokines involved in B cell function. J Immunol. 1991; 146: 3462-3568. PubMed: https://pubmed.ncbi.nlm.nih.gov/2026875/
  5. Dienz O, Eaton SM, Bond JP, Neveu W, Moquin D, et al. The induction of antibody production by IL-6 is indirectly mediated by IL-21 produced by CD4+ T cells. J Exp Med. 2009; 206: 69-78. PubMed: https://pubmed.ncbi.nlm.nih.gov/19139170/
  6. Bettelli E, Carrier Y, Gao W, Korn T, Strom TB, et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature. 2006; 441: 235-238. PubMed: https://pubmed.ncbi.nlm.nih.gov/16648838/
  7. Lee W, Lee GR. Transcriptional regulation and development of regulatory T cells. Exp Mol Med. 2018; 50: e456. PubMed: https://pubmed.ncbi.nlm.nih.gov/29520112/
  8. Bao W, Yu J, Heck S, Yazdanbakhsh K. Regulatory T-cell status in red cell alloimmunized responder and nonresponder mice. Blood. 2009; 113: 5624-5627. PubMed: https://pubmed.ncbi.nlm.nih.gov/19336757/
  9. Martin J, Worthington J, Harris S, Martin S. The influence of class II transactivator and interleukin-6 polymorphisms on the production of antibodies to donor human leucocyte antigen mismatches in renal allograft recipients. Int J Immunogenet. 2009; 36: 235-239. PubMed: https://pubmed.ncbi.nlm.nih.gov/19523152/
  10. Fishman D, Faulds G, Jeffery R, Mohamed-Ali V, Yudkin JS, et al. The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J Clin Invest. 1998; 102: 1369-1376. PubMed: https://pubmed.ncbi.nlm.nih.gov/9769329/
  11. Lee YH, Bae SC, Choi SJ, Ji JD, Song GG. The association between interleukin-6 polymorphisms and rheumatoid arthritis: a meta-analysis. Inflamm Res. 2012; 61: 665-671. PubMed: https://pubmed.ncbi.nlm.nih.gov/22427231/
  12. Pan M, Gao SP, Jiang MH, Guo J, Zheng JG, et al. Interleukin 6 promoter polymorphisms in normal Han Chinese population: frequencies and effects on inflammatory markers. J Investig Med. 2011; 59: 272-276. PubMed: https://pubmed.ncbi.nlm.nih.gov/21157373/
  13. Lin JS, Lee LH, Liu HM, Chen YJ, Chiou TJ. Association of IL-6 C-572G Gene Polymorphism with Anti-E Production. Transfus Med Hemother. 2018; 45: 48-52. PubMed: https://pubmed.ncbi.nlm.nih.gov/29593460/
  14. Mazzatti DJ, Malavolta M, White AJ, Costarelli L, Giacconi R, et al. Effects of interleukin-6 -174C/G and metallothionein 1A +647A/C single-nucleotide polymorphisms on zinc-regulated gene expression in ageing. Exp Gerontol. 2008; 43: 423-432.
  15. Quillen K, Medrano C, Adams S, Peterson B, Hackett J, et al. Screening plateletpheresis donors for HLA antibodies on two high-throughput platforms and correlation with recipient outcome. Transfusion. 2011; 51: 504-510. PubMed: https://pubmed.ncbi.nlm.nih.gov/20849407/
  16. Schnaidt M, Wernet D. Platelet-specific antibodies in female blood donors after pregnancy. Transfus Med. 2000; 10: 77-80. PubMed: https://pubmed.ncbi.nlm.nih.gov/10760206/
  17. Koerner TA, Weinfeld HM, Bullard LS, Williams LC. Antibodies against platelet glycosphingolipids: detection in serum by quantitative HPTLC-autoradiography and association with autoimmune and alloimmune processes. Blood. 1989; 74: 274-284. PubMed: https://pubmed.ncbi.nlm.nih.gov/2752115/
  18. Constant SL, Bottomly K. Induction of Th1 and Th2 CD4+ T cell responses: the alternative approaches. Annu Rev Immunol. 1997; 15: 297-322. PubMed: https://pubmed.ncbi.nlm.nih.gov/9143690/
  19. Kishimoto T. The biology of interleukin-6. Blood. 1989; 74: 1-10. PubMed: https://pubmed.ncbi.nlm.nih.gov/2473791/
  20. Strestik BD, Olbrich AR, Hasenkrug KJ, Dittmer U. The role of IL-5, IL-6 and IL-10 in primary and vaccine-primed immune responses to infection with Friend retrovirus (Murine leukaemia virus). J Gen Virol. 2001; 82: 1349-1354. PubMed: https://pubmed.ncbi.nlm.nih.gov/11369878/
  21. Friedman DF, Lukas MB, Jawad A, Larson PJ, Ohene-Frempong K, et al. Alloimmunization to platelets in heavily transfused patients with sickle cell disease. Blood. 1996; 88: 3216-3222. PubMed: https://pubmed.ncbi.nlm.nih.gov/8874223/
  22. Verduin EP, Brand A, Schonewille H. Is female sex a risk factor for red blood cell alloimmunization after transfusion? a systematic review. Transfus Med Rev. 2012; 26: 342-353. PubMed: https://pubmed.ncbi.nlm.nih.gov/22244869/
  23. Sharpe CJ, Liwski RS, Couban S, Sadek I, Kahwash EB. HLA- and HPA-alloimmunization rate in the setting of refractoriness to platelet transfusion: a single center study. Blood. 2011; 118: 3366.
  24. Wang J, Xia W, Deng J, Xu X, Shao Y, et al. Analysis of platelet-reactive alloantibodies and evaluation of cross-match-compatible platelets for the management of patients with transfusion refractoriness. Transfus Med. 2018; 28: 40-46. PubMed: https://pubmed.ncbi.nlm.nih.gov/28516675/
  25. Kiefel V, Konig C, Kroll H, Santoso S. Platelet alloantibodies in transfused patients. Transfusion. 2001; 41: 766-7670. PubMed: https://pubmed.ncbi.nlm.nih.gov/11399817/
  26. Novotny VM, Doxiadis, II, Brand A. The reduction of HLA class I expression on platelets: a potential approach in the management of HLA-alloimmunized refractory patients. Transfus Med Rev. 1999; 13: 95-105. PubMed: https://pubmed.ncbi.nlm.nih.gov/10218233/
  27. Snyder EL. Prevention of HLA alloimmunization: role of leukocyte depletion and UV-B irradiation. Yale J Biol Med. 1990; 63: 419-427. PubMed: https://pubmed.ncbi.nlm.nih.gov/2293501/
  28. Vamvakas EC. Meta-analysis of randomized controlled trials of the efficacy of white cell reduction in preventing HLA-alloimmunization and refractoriness to random-donor platelet transfusions. Transfus Med Rev. 1998; 12: 258-270. PubMed: https://pubmed.ncbi.nlm.nih.gov/9798269/
  29. Seftel MD, Growe GH, Petraszko T, Benny WB, Le A, et al. Universal prestorage leukoreduction in Canada decreases platelet alloimmunization and refractoriness. Blood. 2004; 103: 333-339. PubMed: https://pubmed.ncbi.nlm.nih.gov/12958065/
  30. Schonewille H, Haak HL, van Zijl AM. Alloimmunization after blood transfusion in patients with hematologic and oncologic diseases. Transfusion. 1999; 39: 763-771. PubMed: https://pubmed.ncbi.nlm.nih.gov/10413286/
  31. Reinhardt D, Houliara K, Pekrun A, Lakomek M, Krone B. Impact of conventional chemotherapy on levels of antibodies against vaccine-preventable diseases in children treated for cancer. Scand J Infect Dis. 2003; 35: 851-857. PubMed: https://pubmed.ncbi.nlm.nih.gov/14723361/
  32. Asfour M, Narvios A, Lichtiger B. Transfusion of RhD-incompatible blood components in RhD-negative blood marrow transplant recipients. MedGenMed. 2004; 6: 22. PubMed: https://pubmed.ncbi.nlm.nih.gov/15520646/
  33. Arora K, Kelley J, Sui D, Ning J, Martinez F, et al. Cancer type predicts alloimmunization following RhD-incompatible RBC transfusions. Transfusion. 2017; 57: 952-928. PubMed: https://pubmed.ncbi.nlm.nih.gov/28191636/

Similar Articles

Recently Viewed

Read More

Most Viewed

Read More